title: Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
abstract: The present study analyzed the outcomes of patients with early-stage hypopharyngeal squamous cell carcinoma (HPSCC) treated with radical radiotherapy (RT) or concurrent chemoradiotherapy (CCRT). We retrospectively reviewed the clinical records of 33 patients with early-stage HPSCC who underwent RT or CCRT between January 1999 and December 2011. Of the 33 patients who were treated, 12 had Stage I and 21 had Stage II disease. Patients with Stage I were typically treated with RT, while patients with Stage II were treated with CCRT (concurrent chemotherapy: 5FU, cisplatin or TS-1). The median follow-up period was 81 months, ranging from 15 to 155 months. The 5-year overall survival rates, cause specific survival rates, locoregional control rates, and progression-free survival rates were 58, 75, 56, and 49 %, respectively. Of the 33 patients, 51 % experienced second primary malignancies. Esophageal carcinoma occurred in several cases, and was diagnosed either during screening after treatment for the second primary malignancy or simultaneously with the second primary malignancy. Advanced-stage second malignancies significantly influenced the survival of the patients and the control rate for HPSCC. Treatment emphasizing the quality of life after treatment is needed, if a poor prognosis is expected because of advanced-stage second primary malignancy.
authors.affiliation: Department of Head and Neck Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan, satou.kaname23@gmail.com.
authors.forename: Kaname
authors.initials: K
authors.lastname: Sato
authors.forename: Akira
authors.initials: A
authors.lastname: Kubota
authors.forename: Madoka
authors.initials: M
authors.lastname: Furukawa
authors.forename: Yousuke
authors.initials: Y
authors.lastname: Kitani
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nonaka
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Mizoguchi
authors.forename: Miho
authors.initials: M
authors.lastname: Shiomi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000473:pathology / Q000556:secondary; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D011829:Radiation Dosage; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil